Marek Hus

Medical University of Lublin — Poland

Medicine · Health Sciences

23h-index2.2kcitations264works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(105), Chronic Lymphocytic Leukemia Research(54), Protein Degradation and Inhibitors(36), Myeloproliferative Neoplasms: Diagnosis and Treatment(31), Lymphoma Diagnosis and Treatment(28)

Publications264 total

Vaccination in paroxysmal nocturnal hemoglobinuria patients treated with terminal and proximal complement inhibitors — Polish Expert Consensus
Acta Haematologica Polonica·2025Open Access
Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study
Blood·2025Open Access
Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis
Blood·2025Open Access
Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study
Blood·2025
Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study
Blood·2025Open Access
Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial
Blood·2025Open Access
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Blood·2025Open Access
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study
Blood·2025
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)
Blood·2025· 1 cited
Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Blood·2025
Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group
Blood·2025
Management of breakthrough hemolysis, thromboembolic complications and pregnancy in patients with paroxysmal nocturnal hemoglobinuria — a position paper
Acta Haematologica Polonica·2025Open Access
Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM
Clinical Lymphoma Myeloma & Leukemia·2025
Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials
Clinical Lymphoma Myeloma & Leukemia·2025
Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
Clinical Lymphoma Myeloma & Leukemia·2025
DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 Study
Clinical Lymphoma Myeloma & Leukemia·2025
Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
KD-PACE chemotherapy regimen as a salvage therapy for aggressive, refractory multiple myeloma
Acta Haematologica Polonica·2025Open Access
ORAL ABSTRACT: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 14Next →

Frequent Co-authors

Anna Dmoszyńska(9), Grzegorz Helbig(9), Sylwia Chocholska(9), Sławomira Kyrcz‐Krzemień(9), Aneta Szudy‐Szczyrek(8), Sebastian Grosicki(7), Norbert Grząśko(7), Roman Hájek(6), Michał Mielnik(6), Dariusz Jawniak(6), Joanna Mańko(6), Meletios Α. Dimopoulos(5), Aaron T. Gerds(5), Vikas Gupta(5), Marta Morawska(5), Agnieszka Szymczyk(5), Joanna Drozd‐Sokołowska(5), Paweł Robak(4), Srđan Verstovšek(4), Jean‐Jacques Kiladjian(4)